Preliminary Safety and Efficacy Results from an Open-Label, Multicenter, Phase 1 Study of RP2 As a Single Agent and in Combination with Nivolumab in a Cohort of Patients with Uveal Melanoma.
JOURNAL OF CLINICAL ONCOLOGY（2023）
关键词
Uveal Melanoma,Retinoblastoma
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要